AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20368220
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg, daily)
Trial: 7988349
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (control group A)
Trial: 11196741
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available MMR vaccine (MMR-II, Merck)
Trial: 10660867
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg.kg-1)
Trial: 30566712
Drug: Intraoperative PFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative PFC injection
Trial: 30566712
Drug: No PFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PFC injection (Control)
Trial: 27491822
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of the blood level of the biomarker soluble urokinase plasminogen activator receptor (suPAR) within 2 hours after admission, with immediate reporting to treating physicians in the ED.
Trial: 18373577
Drug: Tailored daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored daily messages via cellphone prompting to enhance diabetic self-care behaviour
Trial: 16078923
Drug: Apheresis platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apheresis platelets treated with riboflavin (500 micromol per L) and UV light (6.2 J per mL)
Trial: 10915328
Drug: Hierarchical grading
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hierarchical grading systems (e.g., grades I, II, and III)
Trial: 26964157
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (cetirizine hydrochloride)
Trial: 21300334
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist administered from day 2 of the menstrual cycle for 3 consecutive days, followed by standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Trial: 21300334
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with daily injections of recombinant FSH (rFSH) starting on day 2 of the cycle at a dose of 150-225 IU/day, and GnRH antagonists from cycle day 7 onward.
Trial: 7804974
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of live vaccinia vaccine virus (V), 10(5.4) TCID50/ml, administered once a week for 13 weeks and then once every 2 weeks for an additional 39 weeks
Trial: 8646509
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of live vaccinia vaccine virus (V)
Trial: 30561729
Drug: High hemoglobin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hemoglobin group (12.5-13.5 g/dL)
Trial: 30561729
Drug: Low hemoglobin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hemoglobin group (10.5-11.5 g/dL)
Trial: 29504369
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with high dose Dermatophagoides farinae
Trial: 26576716
Drug: Autonomic Regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic Regulation Therapy (ART) via vagus nerve stimulation (VNS)
Trial: 23985355
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy, no restrictions on frequency, duration, or contents.
Trial: 20104222
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg per day in 6-week cycles (4 weeks on, 2 weeks off treatment)
Trial: 12008859
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg subcutaneously twice weekly
Trial: 16128597
Drug: Colestilan (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan (four tablets administered in divided doses with three glasses of water before dinner and bedtime for 12 weeks)
Trial: 6986746
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group of patients with 3 or more and 4 or more hours of treatment
Trial: 31358408
Drug: 3-dose vaccination
RxNorm normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose vaccination (3D) at 7-day post-booster
Trial: 26626341
Drug: Hospital-based Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based Direct Observation of Treatment (HBDOT)
Trial: 22872005
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 μg/kg/day for 3 consecutive days with an additional half-dose 4 hours before surgery)
Trial: 15516942
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no G-CSF)
Trial: 21455076
Drug: Infrapatellar nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrapatellar nerve block (IPNB; 10 ml levobupivacaine 0.5%)
Trial: 1512807
Drug: Matching clients
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching clients to alternative treatment strategies; specific strategies not detailed.
Trial: 6747752
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (0.5 ml) DTP vaccine
Trial: 6747752
Drug: Modified dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dose (0.25 ml) DTP vaccine
Trial: 30045425
Drug: Snack containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snack containing green leafy vegetables, fruit, and milk (mean 54.1 mg ALA)
Trial: 30045425
Drug: Control snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control snack containing low micronutrient foods (mean 4.1 mg ALA)
Trial: 10862807
Drug: Daily buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buprenorphine (16 mg/70 kg)
Trial: 10862807
Drug: Thrice-weekly buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly buprenorphine (34 mg/70 kg on Fridays and Sundays, 44 mg/70 kg on Tuesdays)
Trial: 374194
Drug: Control preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control preparation
Trial: 3351689
Drug: Theophylline plus
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline plus diuretics
Trial: 26209163
Drug: Circumferential topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential topical anesthetic blockade of skin surrounding the wrist
Trial: 30056355
Drug: Intramyometrial vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramyometrial vasopressin plus rectal misoprostol (30 min before procedure)
Trial: 24700631
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training group (19 boys, 22 girls) training twice a week for 8 weeks
Trial: 24700631
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training group (21 boys, 24 girls) training twice a week for 8 weeks
Trial: 7668039
Drug: WC/rBS cholera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC/rBS cholera vaccine
Trial: 8267992
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride (50 mmol)
Trial: 4055163
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + l‐methionine (5:1)
Trial: 4055163
Drug: Paracetamol (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1,500 mg)
Trial: 24655552
Drug: Transdermal HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal HRT (50μg/day estradiol alone for days 1-14 and 50μg/day estradiol plus 0.25mg/day norethisterone acetate for days 15-28 for 6 months)
Trial: 24655552
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and transdermal HRT
Trial: 19657689
Drug: 6-month subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month subcutaneous denosumab injection (60 mg) plus weekly oral placebo
Trial: 19657689
Drug: Weekly alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly alendronate tablet (70 mg) plus 6-month subcutaneous placebo injection
Trial: 7547154
Drug: Intensive medication
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medication counselling for 3 months
Trial: 31806533
Drug: Vaccine Information
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Information Statements (VIS) only
Trial: 25854020
Drug: Integrated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated therapy of acupuncture and pingganjianpi decoction
Trial: 25854020
Drug: Haloperidol tablets
RxNorm normalized name: Haloperidol Tablets
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol tablets (0.05 mg/kg per day, twice a day for 30 days)
Trial: 11709334
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg
Trial: 9758289
Drug: Trovafloxacin 200
RxNorm normalized name: trovafloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin 200 mg
Trial: 9626153
Drug: 0.6 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 IU/day recombinant human growth hormone (rhGH)
Trial: 9626153
Drug: 1.2 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 IU/day recombinant human growth hormone (rhGH)
Trial: 9626153
Drug: 1.8 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 IU/day recombinant human growth hormone (rhGH)
Trial: 7897380
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A (720 ELISA units) and hepatitis B (20 micrograms) vaccine
Trial: 30317290
Drug: 1gm acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1gm acetaminophen
Trial: 28962596
Drug: Chiropractic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic treatment individualized to each woman
Trial: 23216412
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg b.d.
Trial: 23216412
Drug: Loxoprofen 60
RxNorm normalized name: loxoprofen 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen 60 mg t.d.s.
Trial: 20864893
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg flumazenil
Trial: 11424245
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose N‐9 products
Trial: 2649213
Drug: 0.05% clobetasol-17-propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol-17-propionate cream
Trial: 19272659
Drug: Incremental acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental acetylcholine (Ach; 20, 50 and 100 microg/min) infusion
Trial: 17008536
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) after inductions 1 and 2
Trial: 7543781
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G-CSF)
Trial: 17008536
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (G-CSF and control)
Trial: 26419871
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with SSGs
Trial: 26419871
Drug: SSGs in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSGs in combination with cultured autologous epidermal cells (ECs)
Trial: 24626433
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg) plus Ezetimibe (10 mg) daily
Trial: 24626433
Drug: Any LDL-C-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any LDL-C-lowering therapy
Trial: 19761983
Drug: Creatinine increase
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine increase (for a 10-mumol/l increase)
Trial: 17209666
Drug: Lercanidipine/enalapril 10mg/20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine/enalapril 10mg/20mg once daily
Trial: 31172172
Drug: Whole eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole eggs (100 g, ∼2 whole eggs per day)
Trial: 31172172
Drug: Yolk-free eggs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yolk-free eggs (100 g, ∼2 yolk-free eggs per day)
Trial: 22086091
Drug: Transforaminal (TF)
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal (TF) epidural steroids
Trial: 22086091
Drug: Interlaminar (IL)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interlaminar (IL) epidural steroids
Trial: 18435479
Drug: Menthol inhalation
RxNorm normalized name: Eucalyptus/Menthol Inhalation Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol inhalation
Trial: 9863113
Drug: Q-wave millimeter
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-wave millimeter microwave (QWMM) irradiation starting 10 days after operation and combined with chemotherapy on the 16th day (Group A)
Trial: 9863113
Drug: Q-wave millimeter
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-wave millimeter microwave (QWMM) irradiation starting immediately after chemotherapy induced peripheral WBC reduction (Group B)
Trial: 8347733
Drug: 10 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/kg body wt. daily s.c. GM-CSF
Trial: 2939636
Drug: prednicarbate 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednicarbate 0.25% in emulsifiable greasy ointment without water
Trial: 2939636
Drug: prednicarbate 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednicarbate 0.25% in w/o emulsion (ointment)
Trial: 2939636
Drug: prednicarbate 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednicarbate 0.25% in o/w emulsion (cream)
Trial: 29705445
Drug: Bitter orange
RxNorm normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter orange (500 mg capsules)
Trial: 29705445
Drug: Lavender (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender (500 mg capsules)
Trial: 20054280
Drug: Corrected C/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrected C/G ratio
Trial: 9745969
Drug: Ephedrine hydrochloride
RxNorm normalized name: Ephedrine Hydrochloride
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine hydrochloride tablets after lunch and before bedtime for 2 months
Trial: 9745969
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatments (imipramine hydrochloride, desmoporessin, ritaline, cetiprin, or behavioral therapy)
Trial: 22348233
Drug: Indomethacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1 mg/kg)
Trial: 30600137
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (QW) 2 mg
Trial: 25535318
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) workshop plus behavioral family intervention (BFI)
Trial: 23235135
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant administration (n = 74)
Trial: 16781986
Drug: Home administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of intravenous methylprednisolone
Trial: 16781986
Drug: Outpatient administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient administration of intravenous methylprednisolone
Trial: 11994701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zafirlukast and loratadine
Trial: 31849027
Drug: Buprenorphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (4 or 6 mg/d)
Trial: 22480818
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/d
Trial: 22480818
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/d (after week 4 for non-responders)
Trial: 12966478
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 20 to 100 mg
Trial: 12966478
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium <20 mg
Trial: 8800985
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dobutamine (5-10 micrograms/kg/min over 5 min)
Trial: 8800985
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dobutamine (20-40 micrograms/kg/min over 3 min)
Trial: 6549194
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before calcitriol administration) with dietary intake of 9.3 mmoles Ca/day
Trial: 29783095
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment initiated prior to release
Trial: 29783095
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment initiated after release
Trial: 27430210
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (Riastap®) 60-70 mg/kg
Trial: 25164471
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy (3 sessions/week for 24 weeks)
Trial: 15805342
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (21 mg)
Trial: 17451401
Drug: Nalmefene 10
RxNorm normalized name: nalmefene 100 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 10 to 40 mg
Trial: 11800375
Drug: Lidocaine-adrenaline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-adrenaline solution (LA)
Trial: 8133114
Drug: Primaquine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (0.25 mg of base/kg of body weight/day over 14 days)
Trial: 8133114
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg of base/kg over 3 days)
Trial: 2550245
Drug: Insulin 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.125 U.kg-1 + placebo
Trial: 2550245
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + hANP
Trial: 789791
Drug: Conventional A/England/42/72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional A/England/42/72 (H3N2) vaccine (X‐37)
Trial: 789791
Drug: Antigenic hybrid
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigenic hybrid (Heq1N2) vaccine (X‐38)
Trial: 22167767
Drug: N(2)-L-alanyl-L-glutamine (GLN)
RxNorm normalized name: N(2)-L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(2)-L-alanyl-L-glutamine (GLN) 0.4 g/kg per day
Trial: 16377979
Drug: Ribose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose supplementation (10 g in 8 oz water)
Trial: 16377979
Drug: Dextrose supplementation
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose supplementation (10 g in 8 oz water)
Trial: 15054512
Drug: Cariporide 120
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariporide 120 mg
Trial: 3777409
Drug: Nalbuphine 20
RxNorm normalized name: nalbuphine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 20 mg